+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

Alcoholic Steatohepatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Alcoholic Steatohepatitis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Chronic Hepatitis C Virus Infection - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Hepatitis C Virus Infection - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 75 Pages
  • Global
From
Clear Cell Renal Cell Carcinoma (ccRCC) - Pipeline Insight, 2025 - Product Thumbnail Image

Clear Cell Renal Cell Carcinoma (ccRCC) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Liver Disease Associated Pruritus - Pipeline Insight, 2025 - Product Thumbnail Image

Liver Disease Associated Pruritus - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Hepatic Cirrhosis - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatic Cirrhosis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Liver Fibrosis- Pipeline Insight, 2025 - Product Thumbnail Image

Liver Fibrosis- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 85 Pages
  • Global
From
Oncocytoma - Pipeline Insight, 2025 - Product Thumbnail Image

Oncocytoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Renal Impairment - Pipeline Insight, 2025 - Product Thumbnail Image

Renal Impairment - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Polycystic Kidney Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Polycystic Kidney Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Liver Cirrhosis - Epidemiology Forecast - 2034 - Product Thumbnail Image

Liver Cirrhosis - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 112 Pages
  • Global
From
Idiopathic Membranous Nephropathy - Epidemiology Forecast - 2034 - Product Thumbnail Image

Idiopathic Membranous Nephropathy - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 69 Pages
  • Global
From
Diabetic Kidney Disease (DKD) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Diabetic Kidney Disease (DKD) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 95 Pages
  • Global
From
Acute Kidney Injury (AKI) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Acute Kidney Injury (AKI) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 90 Pages
  • Global
From
Alport Syndrome - Epidemiology Forecast - 2034 - Product Thumbnail Image

Alport Syndrome - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 63 Pages
  • Global
From
From
From
From
From
Non-Alcoholic Steatohepatitis Market 2025-2033 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis Market 2025-2033

  • Report
  • March 2025
  • 142 Pages
  • Global
From
Gallbladder Treatment - Global Strategic Business Report - Product Thumbnail Image

Gallbladder Treatment - Global Strategic Business Report

  • Report
  • September 2025
  • 472 Pages
  • Global
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more